IGC Pharma (IGC) Non-Current Debt (2010 - 2026)
IGC Pharma (IGC) posted quarterly Non-Current Debt of $917000.0 for Q1 2026, up 584.33% year-over-year from $134000.0 in Q1 2025, and up 194.86% quarter-over-quarter from $311000.0 in Q4 2025.
IGC Pharma (IGC) Non-Current Debt (2010 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Non-Current Debt for 15 consecutive years, with $917000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 584.33% year-over-year to $917000.0; the TTM figure through Mar 2026 stood at $917000.0 (up 584.33% YoY), while the FY2026 annual figure was $917000.0, up 584.33% from the prior year.
- Non-Current Debt improved to $917000.0 in Q1 2026 per IGC's latest filing, from $311000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $917000.0 in Q1 2026 and bottomed at $132000.0 in Q3 2025.
- Historically, Non-Current Debt has averaged $193941.2 across 5 years, with a median of $139000.0 in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Debt plunged 47.83% — and 2026, when it soared 584.33%.
- IGC Pharma's Non-Current Debt stood at $141000.0 in 2022, then fell by 2.13% to $138000.0 in 2023, then dropped by 2.9% to $134000.0 in 2024, then soared by 132.09% to $311000.0 in 2025, then soared by 194.86% to $917000.0 in 2026.
- Business Quant data shows IGC's Non-Current Debt at $917000.0 in Q1 2026, $311000.0 in Q4 2025, and $132000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 917,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 917,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Sep 30, 2023 | 139,000.00 |
| Jun 30, 2023 | 140,000.00 |
| Mar 31, 2023 | 141,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 142,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Mar 31, 2022 | 144,000.00 |
| Dec 31, 2021 | 145,000.00 |
| Sep 30, 2021 | 146,000.00 |
| Jun 30, 2021 | 147,000.00 |